Prognostic and Therapeutic Significance of BTN3A Proteins in Tumors

Chen, Sihan; Li, Zhangyun; Huang, Wen‐Yi; Wang, Yanyan; Fan, Shao‐Hua

doi:10.7150/jca.57831

Cited by 15 publications

(12 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, it is reasonable to hypothesize that a high expression of IFIT2 plays a role in the anti-ESCC process. The role of BTN3A3 is expected to become a potential therapeutic target for breast cancer (30), and the upregulation of BTN3A3 has been significantly correlated with better overall and relapse-free survival (31). Moreover, it has been noted to be a novel prognostic factor for hepatocellular carcinoma (32).…”

Section: Discussionmentioning

confidence: 99%

Use of exosome transcriptome-based analysis to identify novel biomarkers in patients with locally advanced esophageal squamous cell carcinoma undergoing neoadjuvant chemoradiotherapy

Yang¹,

Zhang²,

Liu³

et al. 2023

Ann Transl Med

View full text Add to dashboard Cite

Background: The prognosis of esophageal squamous cell carcinoma (ESCC) is improved by neoadjuvant chemoradiotherapy (nCRT), especially for patients with pathologic complete response (pCR). Despite the efforts to predict treatment response using multimodality, no molecule has proven to be a strong biomarker.This study aimed to profile the expression of exosome transcriptome that could predict pCR in ESCC before and after nCRT.Methods: We collected paired blood samples of 15 patients with ESCC who received nCRT and radical surgery. They were divided into 3 groups: (A) residual tumor in the first clinical response evaluation (CRE-1), (B) no residual tumor in CRE-1 but with residual tumor in CRE-2 which was performed after 5-6 weeks, and (C) no residual tumor in CRE-1 or CRE-2. For each patient, the blood sample was collected before nCRT (time point 0); and then 6 weeks after nCRT, the clinical response was evaluated, and another blood sample was collected (time point 1).Results: Using the intersection of different sets, we found 23 progression-associated messenger RNAs (mRNAs) and 67 remission-associated mRNAs. Between remission-associated mRNAs and the targets of progression-associated (carcinogenic) microRNAs (miRNAs), the intersection was acquired, and 2 miRNA-mRNA networks (IFIT2-miR-3615-IFIT2-miR-484 and BTN3A3-miR-6803-3p) were identified. Among the intersection of progression-associated (carcinogenic) mRNAs and the targets of remission-associated miRNAs, there is a network with miR-132-3p (remission-associated miRNA) located at the core, matched with DICER1, KLHL8, ANKRD12, ASH1L, and IMP4.Conclusions: Our findings identified altered plasma exosome RNAs among the different groups and between different time points of nCRT, as well as the corresponding enrichments and regulatory networks, which may serve as potentially predictors of treatment response for patients with ESCC after nCRT.

show abstract

Section: Discussionmentioning

confidence: 99%

Use of exosome transcriptome-based analysis to identify novel biomarkers in patients with locally advanced esophageal squamous cell carcinoma undergoing neoadjuvant chemoradiotherapy

Yang¹,

Zhang²,

Liu³

et al. 2023

Ann Transl Med

View full text Add to dashboard Cite

show abstract

“…BTN3A1 belongs to the BTN3A family, which is part of a type I transmembrane protein of the immunoglobulin (Ig) superfamily. The expression levels of BTN3A family members are different among various tumours, which has a crucial impact on tumour prognosis 23 . In patients with melanoma, the expression of BTN3A is increased in pDC cells and γδ T cells; dysfunctional BTN3A leads to defective interaction between pDC and γδ T cells, affecting clinical results 24 .…”

Section: Discussionmentioning

confidence: 99%

A novel prognostic model for cutaneous melanoma based on an immune-related gene signature and clinical variables

Tang

Feng

Zhang

et al. 2022

Sci Rep

View full text Add to dashboard Cite

Abundant evidence has indicated that the prognosis of cutaneous melanoma (CM) patients is highly complicated by the tumour immune microenvironment. We retrieved the clinical data and gene expression data of CM patients in The Cancer Genome Atlas (TCGA) database for modelling and validation analysis. Based on single-sample gene set enrichment analysis (ssGSEA) and consensus clustering analysis, CM patients were classified into three immune level groups, and the differences in the tumour immune microenvironment and clinical characteristics were evaluated. Seven immune-related CM prognostic molecules, including three mRNAs (SUCO, BTN3A1 and TBC1D2), three lncRNAs (HLA-DQB1-AS1, C9orf139 and C22orf34) and one miRNA (hsa-miR-17-5p), were screened by differential expression analysis, ceRNA network analysis, LASSO Cox regression analysis and univariate Cox regression analysis. Their biological functions were mainly concentrated in the phospholipid metabolic process, transcription regulator complex, protein serine/threonine kinase activity and MAPK signalling pathway. We established a novel prognostic model for CM integrating clinical variables and immune molecules that showed promising predictive performance demonstrated by receiver operating characteristic curves (AUC ≥ 0.74), providing a scientific basis for predicting the prognosis and improving the clinical outcomes of CM patients.

show abstract

“…Yamashiro et al found that the expression level of BTN3 was inversely correlated to the activity of lymphocytes, and administration of the mAb 232-5 lead to phosphorylation of the BTN3A3 molecule and transduction of negative signals; these effects caused CD4+ and CD8+ T cells to act like CD4 + CD25+ Tregs, accompanied by a decrease in cell proliferation and cytokine secretion [ 157 ]. However, the mAb 20.1 has no significant stimulatory or costimulatory effect on αβT cells [ 154 ], suggesting that BTN proteins may jointly inhibit effector T cells through negative signal transmission and that BTN3A3 may be a novel target [ 158 ]. In addition, although the mAb 103.2 does not affect the proliferation and activation of CD8+ T cells, it can inhibit the response of γδT cells induced by PAgs and even inhibit the degranulation and cytokine secretion of Vγ9Vδ2T cells, decreasing their antitumor effects.…”

Section: Targeting Ics Can Regulate the Immune Function Of γδT Cellsmentioning

confidence: 99%

Gamma delta T-cell-based immune checkpoint therapy: attractive candidate for antitumor treatment

et al. 2023

View full text Add to dashboard Cite

As a nontraditional T-cell subgroup, γδT cells have gained popularity in the field of immunotherapy in recent years. They have extraordinary antitumor potential and prospects for clinical application. Immune checkpoint inhibitors (ICIs), which are efficacious in tumor patients, have become pioneer drugs in the field of tumor immunotherapy since they were incorporated into clinical practice. In addition, γδT cells that have infiltrated into tumor tissues are found to be in a state of exhaustion or anergy, and there is upregulation of many immune checkpoints (ICs) on their surface, suggesting that γδT cells have a similar ability to respond to ICIs as traditional effector T cells. Studies have shown that targeting ICs can reverse the dysfunctional state of γδT cells in the tumor microenvironment (TME) and exert antitumor effects by improving γδT-cell proliferation and activation and enhancing cytotoxicity. Clarification of the functional state of γδT cells in the TME and the mechanisms underlying their interaction with ICs will solidify ICIs combined with γδT cells as a good treatment option.

show abstract

Prognostic and Therapeutic Significance of BTN3A Proteins in Tumors

Cited by 15 publications

References 67 publications

Use of exosome transcriptome-based analysis to identify novel biomarkers in patients with locally advanced esophageal squamous cell carcinoma undergoing neoadjuvant chemoradiotherapy

Use of exosome transcriptome-based analysis to identify novel biomarkers in patients with locally advanced esophageal squamous cell carcinoma undergoing neoadjuvant chemoradiotherapy

A novel prognostic model for cutaneous melanoma based on an immune-related gene signature and clinical variables

Gamma delta T-cell-based immune checkpoint therapy: attractive candidate for antitumor treatment

Contact Info

Product

Resources

About